Track Shattuck Labs, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Shattuck Labs, Inc. STTK · Stock Open Shattuck Labs, Inc. in new tab

4.65 USD
EPS
-0.47
P/B
2.44
ROE
-47.21
Beta
1.13
Target Price
15.40 USD
Loading chart...
Key Metrics
Earnings dateMarch 4, 2027
EPS-0.47
Book Value1.90
Price to Book2.44
Debt/Equity1.27
% Insiders4.266%
Growth
Revenue Growth-0.67%
Estimates
Forward P/E-8.06
Forward EPS-0.58
Target Mean Price15.40

DCF valuation

Model fair value for Shattuck Labs, Inc. (STTK)
Result
Sign in to run the valuation for STTK.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 15.40 USD (low 10.00, high 19.00) · as of 15 Nov 2026
Low 10.00
Mean 15.40
High 19.00
Price 4.65
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Shattuck Labs, Inc. Logo Shattuck Labs, Inc. Analysis (STTK)

United States Health Care Official Website Stock

Is Shattuck Labs, Inc. a good investment? Shattuck Labs, Inc. (STTK) is currently trading at 4.65 USD. Market analysts have a consensus price target of 15.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: Shattuck Labs, Inc. is expected to release its next earnings report on March 4, 2027. The market consensus estimate for Forward EPS is -0.58.

Investor FAQ

Does Shattuck Labs, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Shattuck Labs, Inc.?

Shattuck Labs, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 4, 2027. The company currently has a trailing EPS of -0.47.

Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Exchange Ticker
NMS (United States) STTK
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion